AbbVie Inc. Total non-current assets

Total non-current assets of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Total non-current assets growth rates and interactive chart. The sum of all non-current or long-term assets.

Highlights and Quick Summary

  • Total non-current assets for the quarter ending December 30, 2019 was $39.6 Billion (a 0.82% increase compared to previous quarter)
  • Year-over-year quarterly Total non-current assets decreased by -6.52%
  • Annual Total non-current assets for 2019 was $39.6 Billion (a -6.63% decrease from previous year)
  • Annual Total non-current assets for 2018 was $42.4 Billion (a -14.44% decrease from previous year)
  • Annual Total non-current assets for 2017 was $49.6 Billion (a -0.7% decrease from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Total non-current assets of AbbVie Inc.

Most recent Total non-current assetsof ABBV including historical data for past 10 years.

Interactive Chart of Total non-current assets of AbbVie Inc.

AbbVie Inc. Total non-current assets for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 $39,596.0 $39,275.0 $42,042.0 $42,356.0 $39,596.0
2018 $42,407.0 $47,699.0 $47,796.0 $48,898.0 $42,407.0
2017 $49,563.0 $49,910.0 $50,032.0 $50,117.0 $49,563.0
2016 $49,912.0 $50,336.0 $50,420.0 $37,098.0 $49,912.0
2015 $36,736.0 $36,920.0 $36,978.0 $11,291.0 $36,736.0
2014 $11,432.0 $10,899.0 $11,251.0 $11,328.0 $11,432.0
2013 $11,350.0 $11,709.0 $12,248.0 $12,246.0 $11,350.0
2012 $11,654.0 $11,799.24 $11,716.59 $12,210.51 $11,654.0
2011 $12,167.0 $12,167.0
2010 $16,660.56 $12,916.21

Business Profile of AbbVie Inc.

Sector: Medical
Industry: Drugs
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. It offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, it offers AndroGel, a testosterone replacement therapy; CREON, a pancreatic enzyme therapy; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide molecule gonadotropin-releasing hormone antagonist. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; Calico Life Sciences LLC; Cystic Fibrosis Foundation; Dragonfly Therapeutics, Inc.; and Pan-Canadian Pharmaceutical Alliance. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.